User profiles for Kathleen E. DelGiorno

Kathleen E. DelGiorno

Vanderbilt University
Verified email at vanderbilt.edu
Cited by 3211

Cysteine depletion induces pancreatic tumor ferroptosis in mice

MA Badgley, DM Kremer, HC Maurer, KE DelGiorno… - Science, 2020 - science.org
Ferroptosis is a form of cell death that results from the catastrophic accumulation of lipid
reactive oxygen species (ROS). Oncogenic signaling elevates lipid ROS production in many …

[PDF][PDF] EGF receptor is required for KRAS-induced pancreatic tumorigenesis

…, N Teichmann, PK Mazur, KE DelGiorno… - Cancer cell, 2012 - cell.com
Initiation of pancreatic ductal adenocarcinoma (PDA) is definitively linked to activating
mutations in the KRAS oncogene. However, PDA mouse models show that mutant Kras …

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

…, X Yuan, AM Dann, M Ridinger-Saison, KE DelGiorno… - Nature, 2019 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis largely owing to
inefficient diagnosis and tenacious drug resistance. Activation of pancreatic stellate cells (PSCs) …

[HTML][HTML] The role of cystine/glutamate antiporter SLC7A11/xCT in the pathophysiology of cancer

N Jyotsana, KT Ta, KE DelGiorno - Frontiers in Oncology, 2022 - frontiersin.org
SLC7A11/xCT is an antiporter that mediates the uptake of extracellular cystine in exchange
for glutamate. Cystine is reduced to cysteine, which is a rate-limiting precursor in glutathione …

[PDF][PDF] Mutant KRas-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions

GY Liou, H Döppler, KE DelGiorno, L Zhang, M Leitges… - Cell reports, 2016 - cell.com
The development of pancreatic cancer requires the acquisition of oncogenic KRas mutations
and upregulation of growth factor signaling, but the relationship between these is not well …

[PDF][PDF] RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma

…, PG Rani, L Feng, MA Carlson, KE DelGiorno… - Cell, 2015 - cell.com
For the majority of patients with pancreas cancer, the high metastatic proclivity is life limiting.
Some patients, however, present with and succumb to locally destructive disease. A …

[PDF][PDF] Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase

CC DuFort, KE DelGiorno, MA Carlson, RJ Osgood… - Biophysical journal, 2016 - cell.com
Elevated interstitial fluid pressure can present a substantial barrier to drug delivery in solid
tumors. This is particularly true of pancreatic ductal adenocarcinoma, a highly lethal disease …

Stromal reengineering to treat pancreas cancer

IM Stromnes, KE DelGiorno, PD Greenberg… - …, 2014 - academic.oup.com
Pancreatic ductal adenocarcinoma co-opts multiple cellular and extracellular mechanisms
to create a complex cancer organ with an unusual proclivity for metastasis and resistance to …

Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma

CC DuFort, KE DelGiorno, SR Hingorani - Gastroenterology, 2016 - Elsevier
The microenvironment influences the pathogenesis of solid tumors and plays an outsized
role in some. Our understanding of the stromal response to cancers, particularly pancreatic …

PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice

…, LV Peverley, H Bien, JC Hall, KE DelGiorno… - Gastroenterology, 2014 - Elsevier
Background & Aims New drug targets are urgently needed for the treatment of patients with
pancreatic ductal adenocarcinoma (PDA). Nearly all PDAs contain oncogenic mutations in …